Pfizer Inc. (PFE) Reports Results of Phase 3 LYRICA(R) Study


Coming off of big merger news last week, Pfizer Inc. (NYSE:PFE) today has posted top-line results for their phase 3 study of LYRICA(R) (pregabalin) capsules.

The study, which was performed over a 15-week period had a primary objective of observing the efficacy of pregablin to treat chronic post-traumatic peripheral neuropathic pain. In what will likely disappoint shareholders, the company found that the drug did not meet their main effacay endpoint. The complete results of the study will be available on the website. Currently there are no available treatments on the market for post-traumatic pain.The stock increased 2.07% or $0.65 on November 25, hitting $31.98. About 12,644 shares traded hands. PFE has declined 9.59% since April 23, 2015 and is downtrending. It has underperformed by 8.57% the S&P500.

Out of 9 analysts covering Pfizer (NYSE:PFE), 8 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. $51 is the highest target while $38 is the lowest. The $43.33 average target is 35.49% above today’s ($31.98) stock price. Pfizer was the topic in 13 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Argus Research maintained the stock on November 3 with “Buy” rating. S&P Research maintained the shares of PFE in a report on October 28 with “Hold” rating. Finally, Morgan Stanley upgraded the stock to “Overweight” rating in an October 2 report.

The institutional sentiment decreased to 0.87 in Q2 2015. Its down 0.08, from 0.95 in 2015Q1. The ratio fall, as 79 funds sold all Pfizer Inc. shares owned while 775 reduced positions. 114 funds bought stakes while 626 increased positions. They now own 4.28 billion shares or 4.59% less from 4.48 billion shares in 2015Q1.

Northeast Financial Consultants Inc holds 21.33% of its portfolio in Pfizer Inc. for 1.42 million shares. Healthinvest Partners Ab owns 846,000 shares or 14.49% of their US portfolio. Moreover, New England Professional Planning Group Inc. has 12.92% invested in the company for 293,725 shares. The Illinois-based Whitnell & Co. has invested 12.67% in the stock. Barry Investment Advisors Llc, a Massachusetts-based fund reported 333,830 shares.

Since March 6, 2015, the stock had 0 insider purchases, and 3 insider sales for $3.27 million net activity. Cangialosi Loretta V sold 24,704 shares worth $880,646. Olson Laurie J sold 26,000 shares worth $894,155. Hill Charles H sold 42,870 shares worth $1.50 million. Susman Sally sold 46,179 shares worth $1.57 million. The insider Dolsten Mikael sold 58,298 shares worth $2.01 million.

Pfizer Inc. is a global biopharmaceutical company. The company has a market cap of $202.87 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has 23.93 P/E ratio. The Company’s products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others.